Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids). Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus the development activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids). The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease.

Harbor Therapeutics, Inc. develops a proprietary class of adrenal steroid hormones as novel pharmaceuticals and nutraceuticals for human health. The company is headquartered in San Diego, CA.

Manufactures pharmaceuticals and diagnostic substances

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Hollis-Eden Pharmaceuticals is focused on research and development of adrenal steroid hormones as pharmaceuticals for human health. Hollis-Eden Pharmaceuticals offers a hormonal signaling technology platform that develops small molecule compounds. The company offers TRIOLEX, a treatment for type 2 diabetes; and APOPTONE, a treatment for cancer. Hollis-Eden Pharmaceuticals was founded by Richard B. Hollis.

The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo, Michigan, by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. These could be "reduced to a powder under the thumb", a strong marketing argument at the time.

BioVie is pioneering an innovative therapeutic approach targeting ascites due to liver cirrhosis. Ascites, or the accumulation of fluid in the abdomen, is the most common complication of cirrhosis due to NASH (non-alcoholic steatohepatitis), alcoholic liver disease and/or hepatitis C. Ascites affects about 100,000 Americans and many times more worldwide, and contributes substantially to mortality. Our therapy BIV201 is based on a drug that is not yet available in the US but is approved in about 50 countries to treat related complications of liver cirrhosis. The Company, formerly knows as NanoAntibiotics, Inc., recently acquired LAT Pharma LLC. This merger provided our lead development program, BIV201. Following a pre-investigational new drug meeting (“pre-IND”) with the FDA in early 2016, the Company is now assembling its IND package, and may commence a US clinical trial as early as 2017.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

NeurMedix, Inc. is a private company headquartered in San Diego, CA, that operates as a biopharmaceutical company which develops neurological and neuro-degenerative products. The firm was founded by Terren S. Peizer, he is the current CEO of the firm.\nThe company says this about itself: NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders and certain cancers. The company��s new drug candidate has successfully completed 11 pre-clinical, and 6 Phase 1, Phase 1/2, and Phase 2 clinical studies in various inflammatory diseases indicating its broad effect in inhibiting inflammatory cascade without evidence of immunosuppression. In addition to Alzheimer��s Disease, NeurMedix plans to enter clinical trials for the treatment of Parkinson��s Disease and several oncological indications. The company��s focus is on diseases with significant unmet medical needs and commercial potential in order to expedite FDA review, minimize capital requirements and optimize shareholder value.

Markets pharmaceutical specialties & personal products

Harbor Therapeutics, Inc. is the world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals and potential nutraceuticals for human health. The adrenals, triangular glands located above each kidney, produce among other key components of the human metabolome, dozens of steroid hormones and have yielded some of the most successful pharmaceuticals.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Glaxo Laboratories Ltd., part of GSK Plc, is a company headquartered in London, UK. The firm wholesales pharmaceutical goods. It was founded in 1929.

The British Drug Houses Ltd. was engaged in pharmaceutical business. The company was founded by Charles Alexander Hill in 1904 and was headquartered in Poole, the United Kingdom.

Akzo Nobel NV is a holding company, which engages in the manufacture and sale of coating and paint products. engages in the production and marketing of paints and coatings. It operates through the following segments: Decorative Paintings, Performance Paintings, and Corporate and Others. The Decorative Paints segment manufactures and supplies a range of interior and exterior decoration and protection products for professional and do-it-yourself markets. The Performance Coatings segment produces automotive and aerospace; industrial; marine and protective; and powder coatings. The company was founded in 1792 and is headquartered in Amsterdam, Netherlands.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.